Survey

Fingolimod (Gilenya) was recently FDA approved in the treatment of relapsing remitting multiple sclerosis (RRMS). How is your health system covering or planning on covering this new oral disease-modifying therapy (DMT)?

1) We will be/are covering it only for patients who have failed injectable DMTs (both in the interferon class and glatiramer acetate).

2) We will be/are covering it only for patients who have failed injectable DMTs (either an interferon or glatiramer acetate).

3) We will be/are covering it for patients that meet certain criteria. However, the main criteria does not have to be failure of an injectable DMT.

4) We will be/are covering it for patients with a new diagnosis of RRMS only.

5) We will not be covering it at all until more data is available.

6) We have not yet decided how to cover this product.

Digital Edition

Opioid-related mortality associated with daily dose for nonmalignant pain

To confirm your e-newsletter subscription, click here.

To ensure future delivery of email newsletters from Formulary, please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

FDA approves first meningococcal vaccine for infants and toddlers

Low A1C level linked to higher risk of mortality in elderly

Hemoglobin A1C levels below 6% are associated with a small but significant increased risk of mortality in elderly patients, according to a retrospective cohort study published online in Diabetes Care. Read full article.

FDA approves Zytiga for late-stage prostate cancer

FDA has approved abiraterone acetate (Zytiga, Centocor Ortho Biotech), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. Read full article.

FDA approves new treatment for type 2 diabetes

FDA approved linagliptin (Tradjenta, Boehringer Ingelheim and Eli Lilly) tablets, used with diet and exercise, to improve blood glucose control in adults with type 2 diabetes. Read full article.

Meeting Coverage

Long-term combo naproxen/esomeprazole safe, effective

No new or unexpected safety issues occurred during long-term treatment with a fixed-dose combination of naproxen and esomeprazole magnesium (Vimovo) in patients at risk of NSAID-associated upper gastrointestinal ulcers, according to data presented at the annual meeting of the American Academy of Pain Medicine, National Harbor, Md. Read full article.

Consider ER oxymorphone in patients with chronic low back pain, comorbidities

In patients with chronic low back pain with comorbidities such as hypertension, diabetes, and cardiovascular disease, extended-release oxymorphone (Opana ER, Endo Pharmaceuticals) may be a safe and effective alternative, according to a study presented at the annual meeting of the American Academy of Pain Medicine, National Harbor, Md. Read full article.

AMCP names 4 new members to board

The Academy of Managed Care Pharmacy recently installed 4 new members to its board of directors. The new board members were sworn in April 29 at AMCP's 23rd Annual Meeting & Showcase in Minneapolis. Read full article.

Top 5 Web Stories

1. FDA Pipeline Preview, April 2011 (Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy)
   
   
2. Metastatic breast cancer: A review of current and novel pharmacotherapy
   
   
3. Belimumab: A B-lymphocyte stimulator inhibitor for-systemic lupus erythematosus
   
   
4. Health reform controversies pose new challenges for drug plans and healthcare providers
   
   
5. Intensive glycemic management leads to higher mortality in type 2 diabetes mellitus patient